Nick Irwin
About Nick Irwin
Nick Irwin is a Senior Account Specialist in Apheresis Operations at Bristol Myers Squibb in Seattle, Washington, with extensive experience in account management and the healthcare and biotechnology fields.
Current Title and Role at Bristol Myers Squibb
Nick Irwin is currently a Senior Account Specialist in Apheresis Operations at Bristol Myers Squibb. He is based in Seattle, Washington, United States. In his role, he supports the onboarding, training, qualification, and performance management of apheresis collection sites. His focus is on ensuring that the centers in Canada are equipped and managed effectively for CAR T cellular therapies.
Previous Roles at Dendreon
Nick Irwin worked at Dendreon from 2016 to 2020. Initially, he served as a Corporate Production Planner/Scheduler for two years, managing scheduling, manufacturing, and logistics for Provenge, an FDA-approved immunotherapy targeting prostate cancer. He then transitioned to the role of Apheresis Account Manager, where he further contributed to the apheresis operations within the Greater Seattle Area.
Career at TalentWise
Before joining the healthcare field, Nick Irwin had a diverse career at TalentWise, based in the Greater Seattle Area. From 2010 to 2016, he held various positions, including Client Services, Market Development Representative, Corporate Sales Account Executive, and National Sales Account Executive. His roles involved customer service, account management, and sales-focused responsibilities.
Education and Academic Background
Nick Irwin studied Administration at Central Michigan University, where he earned a Bachelor of Science (B.S.) degree. His academic background laid a foundation for his career in customer service, sales, and later, his transition to the healthcare and biotechnology sectors.
Early Career and Transition to Healthcare
Nick Irwin began his career in customer service and account management. Over time, he transitioned into the healthcare and biotechnology fields. His work includes supporting the onboarding and management of apheresis sites for new CAR T cell therapies at Juno/Celgene, within Bristol-Meyers Squibb.